<?xml version='1.0' encoding='utf-8'?>
<document id="20110020"><sentence text="Tapentadol hydrochloride: a centrally acting oral analgesic."><entity charOffset="0-24" id="DDI-PubMed.20110020.s1.e0" text="Tapentadol hydrochloride" /></sentence><sentence text="Tapentadol hydrochloride is a centrally acting oral analgesic approved by the US Food and Drug Administration in November 2008 for the treatment of moderate to severe acute pain"><entity charOffset="0-24" id="DDI-PubMed.20110020.s2.e0" text="Tapentadol hydrochloride" /></sentence><sentence text=" It is available as immediate-release 50-, 75-, and 100-mg tablets" /><sentence text="" /><sentence text="The purpose of this article is to review animal studies, pharmacokinetic studies, drug-drug interaction studies, and Phase II/III trials of tapentadol in various conditions producing moderate to severe pain"><entity charOffset="140-150" id="DDI-PubMed.20110020.s5.e0" text="tapentadol" /></sentence><sentence text=" Efficacy and tolerability data from these studies are summarized" /><sentence text="" /><sentence text="A search of MEDLINE and International Pharmaceutical Abstracts was conducted from January 2005 through June 30, 2009" /><sentence text=" Search terms included tapentadol, tapentadol hydrochloride, and (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride"><entity charOffset="23-33" id="DDI-PubMed.20110020.s9.e0" text="tapentadol" /><entity charOffset="35-59" id="DDI-PubMed.20110020.s9.e1" text="tapentadol hydrochloride" /><entity charOffset="65-141" id="DDI-PubMed.20110020.s9.e2" text="(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride" /><pair ddi="false" e1="DDI-PubMed.20110020.s9.e0" e2="DDI-PubMed.20110020.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20110020.s9.e0" e2="DDI-PubMed.20110020.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20110020.s9.e0" e2="DDI-PubMed.20110020.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20110020.s9.e1" e2="DDI-PubMed.20110020.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20110020.s9.e1" e2="DDI-PubMed.20110020.s9.e2" /></sentence><sentence text=" Relevant information was extracted from the identified articles, and the reference lists of these articles were reviewed for additional pertinent publications" /><sentence text=" The manufacturer was contacted for clinical trials, abstracts, and poster presentations that were not identified by the literature search" /><sentence text=" ClinicalTrials" /><sentence text="gov was searched to identify recently completed studies" /><sentence text="" /><sentence text="Tapentadol produces analgesia through a dual mechanism of action: mu-opioid-receptor activation and norepinephrine reuptake inhibition"><entity charOffset="0-10" id="DDI-PubMed.20110020.s15.e0" text="Tapentadol" /><entity charOffset="100-114" id="DDI-PubMed.20110020.s15.e1" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.20110020.s15.e0" e2="DDI-PubMed.20110020.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20110020.s15.e0" e2="DDI-PubMed.20110020.s15.e1" /></sentence><sentence text=" Its efficacy has been reported in a number of animal studies, as well as in Phase II/III clinical trials" /><sentence text=" Primary pain disorders in which efficacy has been reported include dental extraction pain, pain after bunionectomy surgery, osteoarthritis pain of the knee and hip, and low back pain" /><sentence text=" Major adverse effects reported in Phase II/III trials primarily involved the gastrointestinal system (2%-66% of subjects) and the central nervous system (4%-65% of subjects)" /><sentence text=" The occurrence of gastrointestinal adverse effects appeared to be less frequent in tapentadol recipients than in those receiving oxycodone"><entity charOffset="84-94" id="DDI-PubMed.20110020.s19.e0" text="tapentadol" /><entity charOffset="130-139" id="DDI-PubMed.20110020.s19.e1" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.20110020.s19.e0" e2="DDI-PubMed.20110020.s19.e0" /><pair ddi="false" e1="DDI-PubMed.20110020.s19.e0" e2="DDI-PubMed.20110020.s19.e1" /></sentence><sentence text="" /><sentence text="Tapentadol appears to be a well-tolerated and effective analgesic for the treatment of moderate to severe acute pain"><entity charOffset="0-10" id="DDI-PubMed.20110020.s21.e0" text="Tapentadol" /></sentence><sentence text=" Although not currently approved for the management of chronic pain, tapentadol has been reported to be effective in managing pain associated with osteoarthritis and low back pain"><entity charOffset="69-79" id="DDI-PubMed.20110020.s22.e0" text="tapentadol" /></sentence><sentence text="" /></document>